Safety of the standardized quality tree sublingual immunotherapy tablet: Pooled safety analysis of clinical trials

The standardized quality (SQ) tree sublingual immunotherapy (SLIT)‐tablet has recently been approved for treatment of tree pollen allergy. Healthcare workers should be provided with detailed safety data for clinical use.

• Publication year

  2020

• Venue

  Allergy. European Journal of Allergy and Clinical Immunology

• Publication date

  2020-09-28

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/all.14882PMID 33905129
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Safety of Timothy Grass Sublingual Immunotherapy Tablet in Children: Pooled Analyses of Clinical Trials.

  2020cited by this paper
• Safety of allergen immunotherapy in North America from 2008-2017: Lessons learned from the ACAAI/AAAAI National Surveillance Study of adverse reactions to allergen immunotherapy.

  2020cited by this paper
• Birch pollen allergy in Europe

  2019cited by this paper
• The SQ tree SLIT‐tablet is highly effective and well tolerated: Results from a randomized, double‐blind, placebo‐controlled phase III trial

  2019cited by this paper
• Allergic components of eosinophilic esophagitis.

  2018cited by this paper
• A birch sublingual allergy immunotherapy tablet reduces rhinoconjunctivitis symptoms when exposed to birch and oak and induces IgG4 to allergens from all trees in the birch homologous group

  2018cited by this paper
• Immunotherapy With the SQ Tree SLIT-tablet in Adults and Adolescents With Allergic Rhinoconjunctivitis.

  2018cited by this paper
• Sensitization profiles to peanut allergens across the United States.

  2017cited by this paper
• Pollen-food allergy syndrome is a common allergic comorbidity in adults with eosinophilic esophagitis.

  2017cited by this paper
• EAACI guidelines on allergen immunotherapy: Prevention of allergy

  2017cited by this paper
• Local Side Effects of Sublingual and Oral Immunotherapy.

  2017cited by this paper
• Allergen immunotherapy: an updated review of safety

  2017cited by this paper
• Allergen immunotherapy for allergic rhinoconjunctivitis: a systematic overview of systematic reviews

  2017cited by this paper
• A practical guide to the sublingual immunotherapy tablet adverse event profile: implications for clinical practice

  2017cited by this paper
• SQ house dust mite (HDM) SLIT-tablet provides clinical improvement in HDM-induced allergic rhinitis

  2016cited by this paper
• Birch pollen influence the severity of atopic eczema – prospective clinical cohort pilot study and ex vivo penetration study

  2015cited by this paper
• Airborne pollen levels and drug consumption for seasonal allergic rhinoconjunctivitis: a 10‐year study in France

  2015cited by this paper
• EAACI Food Allergy and Anaphylaxis Guidelines: diagnosis and management of food allergy

  2014cited by this paper
• Geographic and temporal variations in pollen exposure across Europe.

  2014cited by this paper
• Efficacy and safety of grass sublingual immunotherapy tablet, MK-7243: a large randomized controlled trial.

  2014cited by this paper
• The influence of sensitisation to pollens and moulds on seasonal variations in asthma attacks

  2013cited by this paper
• SQ-standardized sublingual grass immunotherapy: confirmation of disease modification 2 years after 3 years of treatment in a randomized trial.

  2012cited by this paper
• Birch pollen-related food allergy: clinical aspects and the role of allergen-specific IgE and IgG4 antibodies.

  2011cited by this paper
• Geographical variations in the prevalence of atopic sensitization in six study sites across Canada

  2010cited by this paper
• Urticaria is associated with birch‐pollen sensitization

  2007cited by this paper

• Efficacy of Subcutaneous, Sublingual and Oral Immunotherapy for Allergens: A Comparative Study

  2025cites this paper
• Treatment with the SQ tree sublingual immunotherapy tablet is safe and well tolerated in real‐life

  2024cites this paper
• The SQ tree sublingual immunotherapy tablet is effective and well tolerated in children—A pivotal phase III trial

  2024influential citation
• Safety of local nasal immunotherapy using hypoallergenic birch pollen ointment in patients with pollen-food allergy syndrome: A preliminary study of five cases.

  2024cites this paper
• Local nasal immunotherapy with birch pollen-galactomannan conjugate-containing ointment in mice and humans.

  2023cites this paper
• Mechanisms and biomarkers of successful allergen-specific immunotherapy

  2022cites this paper
• Local nasal immunotherapy for allergic rhinitis: A systematic review and meta‐analysis

  2022cites this paper